直接抗病毒药物与丙型肝炎的长期临床结局：治疗所有疾病的万灵药仍然不存在。 - Suppr | 超能文献

DAAs and long-term clinical outcome in hepatitis C: the panacea for all diseases still does not exist.

作者信息

Perrella Alessandro, Rinaldi Luca, Galeota-Lanza Alfonso, Izzi Antonio

机构信息

VII Department of Infectious Disease and Immunology, Ospedali dei Colli P. O. D. Cotugno, Naples, Italy. Liver Unit, King's College medical School University, London, UK. Gastroenterology Unit, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy. Hepatology Unit, AORN Hospital A. Cardarelli, Naples, Italy. I Division Infectious Disease, Ospedali dei Colli P. O. D. Cotugno, Naples, Italy.

出版信息

Am J Gastroenterol. 2018 Aug;113(8):1251. doi: 10.1038/s41395-018-0062-3.

DOI:10.1038/s41395-018-0062-3

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

DAAs and long-term clinical outcome in hepatitis C: the panacea for all diseases still does not exist.直接抗病毒药物与丙型肝炎的长期临床结局：治疗所有疾病的万灵药仍然不存在。

Am J Gastroenterol. 2018 Aug;113(8):1251. doi: 10.1038/s41395-018-0062-3.

2

[Selection of direct-acting antiviral agents for chronic hepatitis C infection].[慢性丙型肝炎感染直接抗病毒药物的选择]

Zhonghua Gan Zang Bing Za Zhi. 2018 Mar 20;26(3):169-172. doi: 10.3760/cma.j.issn.1007-3418.2018.03.002.

3

[Clinical timing and benefit of antiviral treatment for hepatitis C].

Zhonghua Gan Zang Bing Za Zhi. 2017 Mar 20;25(3):164-169. doi: 10.3760/cma.j.issn.1007-3418.2017.03.002.

4

[A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment].[临床实践中的一项新挑战：丙型肝炎治疗中对直接作用抗病毒药物的耐药性]

Zhonghua Gan Zang Bing Za Zhi. 2016 Mar 20;24(3):165-9. doi: 10.3760/cma.j.issn.1007-3418.2016.03.002.

5

HBV recurrence after HCV clearance on DAAs: Sometimes they come back.在使用直接抗病毒药物清除丙肝病毒后乙肝病毒复发：有时它们会卷土重来。

J Hepatol. 2017 Nov;67(5):898-901. doi: 10.1016/j.jhep.2017.08.017. Epub 2017 Aug 31.

6

[Current management of hepatitis C].[丙型肝炎的当前管理]

Med Monatsschr Pharm. 2015 Sep;38(9):337-44; quiz 345-6.

7

[Research progress of hepatitis C in 2018].

Zhonghua Gan Zang Bing Za Zhi. 2019 Jan 20;27(1):6-9. doi: 10.3760/cma.j.issn.1007-3418.2019.01.003.

8

[Hepatitis C-related hepatocellular carcinoma and the treatment with direct-acting antiviral agents].[丙型肝炎相关肝细胞癌与直接抗病毒药物治疗]

Zhonghua Gan Zang Bing Za Zhi. 2017 Dec 20;25(12):944-947. doi: 10.3760/cma.j.issn.1007-3418.2017.12.013.

9

Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: Too alarming?在直接抗病毒药物（DAAs）时代，丙型肝炎患者肝细胞癌的意外高发病率：是否过于令人担忧？

J Hepatol. 2016 Nov;65(5):1068-1069. doi: 10.1016/j.jhep.2016.07.029. Epub 2016 Jul 28.

10

Antiviral therapy for "difficult-to-treat" hepatitis C virus-infected patients.抗病毒治疗“难治”丙型肝炎病毒感染患者。

Chin Med J (Engl). 2013 Dec;126(23):4568-74.

引用本文的文献

1

Eosinophilic esophagitis in children and adolescents: a clinical practice guideline.儿童和青少年嗜酸性粒细胞性食管炎：临床实践指南

Ital J Pediatr. 2025 Jul 23;51(1):242. doi: 10.1186/s13052-025-02056-x.

2

Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis.探寻丙型肝炎病毒诱导肝癌发生的表观遗传印记

J Clin Med. 2021 Feb 2;10(3):551. doi: 10.3390/jcm10030551.

3

Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics.直接抗病毒药物治疗清除丙型肝炎病毒后肝细胞癌的风险：预测因素及表观遗传学的作用

Cancers (Basel). 2020 May 26;12(6):1351. doi: 10.3390/cancers12061351.

4

Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study.直接作用抗病毒药物治疗的 HCV 患者中 HCC 早期发生的发生率和风险因素：一项前瞻性多中心研究。

J Transl Med. 2019 Aug 28;17(1):292. doi: 10.1186/s12967-019-2033-x.